Building a precision medicine infrastructure at a national level: The Swedish experienceDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics, Karolinska University Hospital, Solna, Sweden .
Lund University Collaboration Office, Lund University, Lund, Sweden.
Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden .
Innovation Partnership Office, Uppsala University, Uppsala, Sweden.
Department of Clinical Pathology, Biological and Clinical Sciences, Linköping University, Linköping, Sweden; Clinical Genomics Linköping, Linköping University, Linköping, Sweden .
Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden .
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Solna, Sweden.
Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden .
Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden; Clinical Genomics Gothenburg, Science for Life Laboratory, University of Gothenburg, Gothenburg, Sweden; Bioinformatics Data Center, Core Facilities, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden .
Genomic Medicine Center Karolinska, Karolinska University Hospital, Stockholm, Sweden; Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Stockholm, Science Life Laboratory, Karolinska Institutet, Solna, Sweden; School of Engineering Sciences in Chemistry, Biotechnology and Health, Clinical Genomics Stockholm, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden .
Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden; Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden; Clinical Genomics Lund, Science for Life Laboratory, Lund University, Lund, Sweden .
Show others and affiliations
2023 (English)In: Cambridge Prisms: Precision Medicine, E-ISSN 2752-6143, Vol. 1, article id e15Article, review/survey (Refereed) Published
Abstract [en]
Precision medicine has the potential to transform healthcare by moving from one-size-fits-all to personalised treatment and care. This transition has been greatly facilitated through new high-throughput sequencing technologies that can provide the unique molecular profile of each individual patient, along with the rapid development of targeted therapies directed to the Achilles heels of each disease. To implement precision medicine approaches in healthcare, many countries have adopted national strategies and initiated genomic/precision medicine initiatives to provide equal access to all citizens. In other countries, such as Sweden, this has proven more difficult due to regionally organised healthcare. Using a bottom-up approach, key stakeholders from academia, healthcare, industry and patient organisations joined forces and formed Genomic Medicine Sweden (GMS), a national infrastructure for the implementation of precision medicine across the country. To achieve this, Genomic Medicine Centres have been established to provide regionally distributed genomic services, and a national informatics infrastructure has been built to allow secure data handling and sharing. GMS has a broad scope focusing on rare diseases, cancer, pharmacogenomics, infectious diseases and complex diseases, while also providing expertise in informatics, ethical and legal issues, health economy, industry collaboration and education. In this review, we summarise our experience in building a national infrastructure for precision medicine. We also provide key examples how precision medicine already has been successfully implemented within our focus areas. Finally, we bring up challenges and opportunities associated with precision medicine implementation, the importance of international collaboration, as well as the future perspective in the field of precision medicine.
Place, publisher, year, edition, pages
Cambridge University Press, 2023. Vol. 1, article id e15
Keywords [en]
Genomic medicine, precision medicine, implementation, national infrastructure
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:oru:diva-105587DOI: 10.1017/pcm.2023.3OAI: oai:DiVA.org:oru-105587DiVA, id: diva2:1751619
Funder
Vinnova2023-04-182023-04-182023-05-30Bibliographically approved